Article
Biochemistry & Molecular Biology
Byung-Hyun Lee, Ji-Hea Kim, Ka-Won Kang, Se-Ryeon Lee, Yong Park, Hwa-Jung Sung, Byung-Soo Kim
Summary: PVR expression in multiple myeloma is associated with poor prognosis and may serve as a potential prognostic marker.
Article
Medicine, General & Internal
Noa Gross Even-Zohar, Marjorie Pick, Liron Hofstetter, Adir Shaulov, Boaz Nachmias, Eyal Lebel, Moshe E. Gatt
Summary: Elevated CD24 expression is strongly correlated with survival in patients with multiple myeloma, and can be used as a prognostic factor for predicting clinical outcomes.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Zhenying Guo, Li Shen, Ningning Li, Xiaoxiao Wu, Canming Wang, Zheng Gu, Zhongjian Chen, Junping Liu, Weimin Mao, Yuchen Han
Summary: This study used bioinformatics to identify key genes in malignant mesothelioma, finding that Aurora-A could be an optimal diagnostic biomarker and a potential prognostic marker. Additionally, seven genes were identified as potential prognostic markers for MM.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Piotr Lacina, Aleksandra Butrym, Diana Frontkiewicz, Grzegorz Mazur, Katarzyna Bogunia-Kubik
Summary: This study demonstrates that serum soluble CD147 (sCD147) may serve as a prognostic marker in multiple myeloma (MM), as its level is higher in MM patients and correlates with disease progression and survival.
CURRENT ISSUES IN MOLECULAR BIOLOGY
(2022)
Article
Oncology
Jiawen Luo, Cong Lai, Xiaoting Xu, Juanyi Shi, Jintao Hu, Kaixuan Guo, Yelisudan Mulati, Yunfei Xiao, Degeng Kong, Cheng Liu, Kewei Xu
Summary: This study found that SPOCK3 affects the malignant progression of prostate cancer and constructed a prognostic model for predicting patient outcomes. The results showed that SPOCK3 expression is significantly associated with immune cell infiltration, and the constructed model has excellent predictive performance.
Article
Multidisciplinary Sciences
Marta Dratwa, Piotr Lacina, Aleksandra Butrym, Diana Porzuczek, Grzegorz Mazur, Katarzyna Bogunia-Kubik
Summary: Telomere dysfunction and hTERT genetic variability may serve as potential prognostic markers in multiple myeloma (MM), as telomere length was shorter in MM patients compared to healthy individuals and patients with advanced disease had shorter telomeres. Patients with certain hTERT genetic variants exhibited shorter progression-free survival.
SCIENTIFIC REPORTS
(2023)
Review
Oncology
Alessandro Allegra, Marco Casciaro, Paola Barone, Caterina Musolino, Sebastiano Gangemi
Summary: This review focuses on the role of epigenetic mechanisms in the development and growth of multiple myeloma, as well as the crosstalk between tumor microenvironment cells and neoplastic cells, introducing the impact of these epigenetic changes on reshaping the tumor microenvironment.
Article
Biochemical Research Methods
Ping Lin, Yuean Zhao, Xiaoqian Li, Zongan Liang
Summary: This study identified several hub genes relevant to Malignant Pleural Mesothelioma (MPM), including NUSAP1, PLOD2, and KIAA0101. Among these genes, KIAA0101 appears to be a useful diagnostic and prognostic biomarker for MPM, which may provide new clues for MPM diagnosis and therapy.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
(2022)
Article
Oncology
Weiqin Yao, Haifei Yang, Hongying You, Jingjing Shang, Yingying Zhai, Zhi Yan, Shuang Yan, Xiaolan Shi, Ying Yao, Jing Wang, Panfeng Wang, Yun Xu, Song Jin, Lingzhi Yan, Depei Wu, Chengcheng Fu
Summary: This study retrospectively analyzed the prognostic value of circulating plasma cells (cPCs) quantified by 10-color flow cytometry in newly diagnosed multiple myeloma (MM) cases. The study found that a high ratio of cPCs is a reliable indicator for predicting a poorer prognosis in MM patients. Incorporating the Revised International Staging System (R-ISS) and cytogenetic risk factors alongside cPC levels enhances the accuracy of prognostic predictions for MM patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Katia Todoerti, Maria Eugenia Gallo Cantafio, Manuela Oliverio, Giada Juli, Carmine Rocca, Rita Citraro, Pierfrancesco Tassone, Antonio Procopio, Giovambattista De Sarro, Antonino Neri, Giuseppe Viglietto, Nicola Amodio
Summary: Synthetic HTOL shows anti-tumor activity against multiple myeloma cells by reducing cell viability without affecting healthy cells, antagonizing key survival pathways for malignant plasma cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Han-ying Huang, Yun Wang, Wei-da Wang, Xiao-li Wei, Robert Peter Gale, Jin-yuan Li, Qian-yi Zhang, Ling-ling Shu, Liang Li, Juan Li, Huan-xin Lin, Yang Liang
Summary: This study aimed to predict the survival of PCM patients by identifying genes related to survival based on plasma cell metabolism. A metabolic risk score was developed and found to improve survival prediction accuracy, as confirmed in in vitro tests with PCM cell lines.
Article
Computer Science, Interdisciplinary Applications
Marzia Settino, Mariamena Arbitrio, Francesca Scionti, Daniele Caracciolo, Giuseppe Agapito, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Teresa Di Martino, Mario Cannataro
Summary: Studying the correlation between gene expression profiling and patient survival in multiple myeloma is essential for understanding the disease progression, and the use of appropriate bioinformatic tools for integrative analysis is crucial.
JOURNAL OF COMPUTATIONAL SCIENCE
(2021)
Article
Medicine, General & Internal
Haipeng Jia, Xiaofen Zhang, Xinxin Liu, Ruifang Qiao, Yan Liu, Sulong Lv, Hongbo Zhu, Jie Wang, Qiuhong Kong, Hong Zhang, Zhirong Zhang
Summary: The study identified multiple myeloma-related abnormal expression of immune-related mRNAs, primarily enriched in B cells-related biological processes and pathways. FABP5 mRNA was confirmed as a key risk factor for multiple myeloma, with its up-regulation usually associated with unfavorable outcomes. There were significant differences in the infiltration levels of various immune cells in multiple myeloma, indicating potential for immunotherapy targeting FABP5 mRNA as a prognostic marker.
FRONTIERS IN MEDICINE
(2021)
Article
Immunology
Tiantian Ma, Jing Shi, Yuxia Xiao, Tianyue Bian, Jincheng Wang, Lingyun Hui, Mengchang Wang, Huasheng Liu
Summary: This study investigated the expression level of BCMA in the bone marrow of multiple myeloma patients and found correlations with disease stability, disease type, and certain prognostic factors, but not with age and serum creatinine levels.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
A. Paschali, E. Panagiotidis, T. Triantafyllou, V. Palaska, K. Tsirou, E. Verrou, E. Yiannaki, D. Markala, A. Papanikolaou, A. Pouli, P. Konstantinidou, V. Chatzipavlidou, E. Terpos, E. Katodritou
Summary: This study demonstrated the correlation between cPC morphology and markers related to MM biology with SUVmax pelvis/liver index, which could serve as a surrogate marker for bone marrow assessment and disease prognosis. Additionally, PET patterns were found to correlate with MM prognostic features and response rates.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Economics
Mimi Choon-Quinones, Dirk Hose, Zoltan Kalo, Tamas Zelei, Jean-Luc Harousseau, Brian Durie, Paul Keown, Mike Barnett, Ivett Jakab
Summary: Decision-aids (DAs) can assist in shared decision-making by providing evidence-based information for healthcare professionals, patients, and caregivers. However, current DAs lack a comprehensive framework of decision factors.
Article
Oncology
Hatice Satilmis, Emma Verheye, Philip Vlummens, Inge Oudaert, Niels Vandewalle, Rong Fan, Jennifer M. Knight, Nathan De Beule, Gamze Ates, Ann Massie, Jerome Moreaux, Anke Maes, Elke De Bruyne, Karin Vanderkerken, Eline Menu, Erica K. Sloan, Kim De Veirman
Summary: This study investigates the potential therapeutic effects of beta-blockers, specifically targeting the beta(2)-adrenergic receptor, in multiple myeloma treatment. The blockade of beta(2)-adrenergic receptors reduces cell viability, induces apoptosis and autophagy, and modulates cancer cell metabolism. Combining beta(2)AR blockade with other drugs enhances apoptosis in multiple myeloma cells.
JOURNAL OF PATHOLOGY
(2023)
Article
Oncology
Elias K. Mai, Stefanie Huhn, Kaya Miah, Alexandra M. Poos, Christof Scheid, Katja C. Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W. Blau, Mathias Haenel, Hans J. Salwender, Axel Benner, Marc S. Raab, Hartmut Goldschmidt, Niels Weinhold
Summary: Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. Our study found that MS negativity was significantly associated with improved progression-free survival (PFS) in multiple myeloma patients, even in those patients with complete response (CR). Combining MS and baseline cytogenetics improved the prediction of outcome, and sequential MS combined with baseline disease features and minimal residual disease (MRD) can further improve its clinical value.
BLOOD CANCER JOURNAL
(2023)
Review
Economics
Mimi Choon-Quinones, Tamas Zelei, Bertalan Nemeth, Manna Toth, Xiao Yang Jia, Mike Barnett, Paul Keown, Brian Durie, Jean-Luc Harousseau, Dirk Hose, Zoltan Kalo
Summary: The aim of this study was to review economic evaluations of health technologies in multiple myeloma (MM) and provide recommendations for future analyses. A systemic literature review was conducted and it was found that most economic analyses were from high-income countries, while evaluations from middle-income countries were rare. Diagnostic technologies and integrated care were rarely modelled, and there was a lack of evaluations regarding minimal residual disease (MRD).
JOURNAL OF MEDICAL ECONOMICS
(2023)
Article
Oncology
Rong Fan, Hatice Satilmis, Niels Vandewalle, Emma Verheye, Philip Vlummens, Anke Maes, Catharina Muylaert, Elke De Bruyne, Eline Menu, Holly Evans, Andrew Chantry, Nathan De Beule, Dirk Hose, Marie Toerngren, Helena Eriksson, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman
Summary: This study reveals the dual therapeutic effects of the immunomodulator tasquinimod in multiple myeloma patients, including inhibition of tumor cell proliferation and promotion of immune activity. The results suggest that tasquinimod can inhibit immunosuppressive myeloid cells in the bone marrow by targeting S100A9, and enhance T cell activity and functionality.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
L. Baert, B. Manfroi, M. Quintero, O. Chavarria, P. V. Barbon, E. Clement, A. Zeller, T. Van Kuppevelt, N. Sturm, J. Moreaux, A. Tveita, B. Bogen, T. McKee, B. Huard
Summary: Multiple myeloma is a hematological neoplasm derived from plasma cells in the bone marrow. A subpopulation of cells called 10e4(+) cells, which have high resistance to multiple myeloma drugs, bind to the protein APRIL through heparan sulfate chains on syndecan-1. These cells have high proliferation activity and are able to form colonies in 3D cultures. They can develop in the bone marrow after intravenous injection and become more resistant to drugs after treatment. The enzyme HS3ST3a1 plays a role in modifying syndecan-1 to confer reactivity to 10e4 and APRIL binding. Targeting this enzyme could potentially improve drug resistance control in multiple myeloma.
Article
Genetics & Heredity
Mohammad Salma, Elina Alaterre, Jerome Moreaux, Eric Soler
Summary: Var vertical bar Decrypt is a web-based tool designed to extract relevant functional information from whole-exome sequencing (WES) data. It offers various filtering and analysis tools for prioritizing gene variants. By using Var vertical bar Decrypt, we successfully identified known disease oncogenes and novel putative drivers in WES datasets of acute erythroid leukemia patients.
EPIGENETICS & CHROMATIN
(2023)
Article
Hematology
Sarah Bonnet, Serge Carillo, Baptiste Legrand, Barbara Burroni, Thierry Lavabre-Bertrand, Guilhem Requirand, Nicolas Robert, Lea Fornero, Ahmed Al Mansoori, Jerome Moreaux, Guillaume Cartron, Ludovic Gabellier, Charles Herbaux
Summary: This case study describes a patient with extreme thrombocytosis who unfortunately had a rapidly fatal outcome. The cause of the thrombocytosis remained unknown and the patient did not show signs of myelofibrosis. However, dysplastic megakaryocytes were observed. The patient had a novel variant of the CALR gene in exon 3 (C105S), as well as mutations in ASXL1, U2AF1, and EZH2. These mutations were found in myeloid cells but not in lymphoid cells. The patient was diagnosed with a rare case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN). Due to the high risk of thrombosis, the patient was treated with hydroxycarbamide. As the hematological status worsened, two new mutations, SETBP1 and ETV6, appeared, while the CALR mutation and the three other mutations identified in the chronic stage were still detectable. These findings suggest that the CALR variant may contribute to the pathogenesis of MDS/MPN in this patient.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2023)
Letter
Oncology
Djamila Chemlal, Emmanuel Varlet, Amelie Machura, Sara Ovejero, Guilhem Requirand, Nicolas Robert, Guillaume Cartron, Elina Alaterre, Caroline Bret, Laure Vincent, Charles Herbaux, Giacomo Cavalli, Angelique Bruyer, Hugues De Boussac, Jerome Moreaux
Article
Medical Laboratory Technology
Emilia Boris, Alexandre Theron, Valentin Montagnon, Nicolas Rouquier, Marion Almeras, Jerome Moreaux, Caroline Bret
Summary: This study aimed to investigate the landscape of 7 leukemia-associated phenotype (LAP) markers in B acute lymphoblastic leukemia (B ALL). The expression levels of these markers in normal leukocytes, normal B cell differentiation, and B lymphoblasts at diagnosis of B ALL were evaluated. The study also examined the prognostic value of these markers using Maxstat R algorithm.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Meeting Abstract
Oncology
Catharina Muylaert, Lien Ann Van Hemelrijck, Elina Alaterre, Nicolas Robert, Guilhem Requirand, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jerome Moreaux, Elke De Bruyne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Inge Oudaert, Judith Lind, Osman Aksoy, Catharina Muylaert, Hatice Satilmis, Sylvia Faict, Jerome Moreaux, Kim De Veirman, Elke De Bruyne, Sonia Vallet, Karin Vanderkerken, Klaus Podar, Eline Menu
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Sara Ovejero, Julie Devin, Tatiana Caneque, Laura Henry, Laura Alibert, Guilhem Requirand, Nicolas Robert, Alizee Steer, Amelie Machura, Christophe Hirtz, Angelique Bruyer, Laure Vincent, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Caroline Bret, Jerome Moreaux
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Laure Dutrieux, Guillemin Antoine, Lin Yea-Lih, Malik Lutzmann, Guilhem Requirand, Nicolas Robert, Laure, Guillaume Cartron, Charles Herbaux, Raphael Rodriguez, Michel Cogne, Philippe Pasero, Jerome Moreaux
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2023)
Meeting Abstract
Oncology
Anja Seckinger, Vanessa Buatois, Valery Moine, Lise Nouveau, Bruno Daubeuf, Sara Majocchi, Ulla Ravn, Nicolas Bosson, Krzysztof Masternak, Yves Poitevin, Giovanni Magistrelli, Pauline Malinge, Limin Shang, Nicolas Fischer, Klaus Strein, Walter Ferlin, Dirk Hose
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)